Safety and Tolerability of Glatiramer Acetate

Exclusion Criteria

• •1. Subject has any contraindication to Glatiramer Acetate therapy
• •2. Subjects with progressive forms of multiple sclerosis (MS).
• •3. Subjects with Neuromyelitis Optica (NMO).
• •4. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
• •5. Concomitant use of other disease modifying drug for MS ((Fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), Teriflunomide (Aubagio®) or intravenous immunoglobulin (IVIG)) within 6 months prior to screening
• •6. Previous use of mitoxantrone, cladribine, alemtuzumab, rituximab, natalizumab.
• •7. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
• •8. Previous total body irradiation or total lymphoid irradiation.
• •9. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
• •10. Pregnancy or breastfeeding.
• •11. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and abnormal laboratory tests. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.
• •12. Subjects who underwent endovascular treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI).
• •13. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals -